PMID- 33491743 OWN - NLM STAT- MEDLINE DCOM- 20210913 LR - 20210913 IS - 1791-2423 (Electronic) IS - 1019-6439 (Linking) VI - 57 IP - 5 DP - 2020 Nov TI - Cisplatin combined with laser‑activated nanotherapy as an adjuvant therapy for head and neck cancer. PG - 1169-1178 LID - 10.3892/ijo.2020.5126 [doi] AB - Head and neck cancers (HNCs), in general, have a poor prognosis with a worldwide 5‑year survival rate of <50%. Numerous HNC patients with locoregionally advanced, difficult‑to‑treat, inoperable, recurrent and drug‑resistant tumors may require additional treatment options when the standard of care surgery, chemotherapy and radiation are not viable. The poor outcomes justify exploring strategies to increase the efficacy of lower doses of drugs, such as cisplatin, by combining these drugs with other treatment modalities and manipulating the dosing schedule. Cisplatin is a standard and effective anticancer drug; however, some patients cannot tolerate the side‑effects or exhibit drug resistance. Adjuvant therapies may lower the effective dose, decrease side‑effects, address drug resistance and improve overall survival outcomes, particularly for patients with difficult‑to‑treat tumors. The present study focuses on combining cisplatin with laser‑activated nanotherapy (LANT), as an adjuvant HNC therapy, with the aim of enhancing the therapeutic efficacy of lower doses of cisplatin and decreasing treatment times. The results demonstrate the potential of cisplatin and LANT co‑therapy as a possible addition to the adjuvant therapy options for HNC using 3 cell lines: Detroit 562, FaDu and CAL 27 cells. Combining cisplatin with LANT demonstrated up to a 5.4‑fold greater therapeutic efficacy than with cisplatin monotreatment. The most effective combination in the present study was 1 microM Cis + 5 nM LANT, which demonstrated cell death comparable to 5.9, 4.2 and 5.3 microM of Cis monotreatment, in Detroit 562, FaDu and CAL 27 cells, respectively. This result suggests that a lower cisplatin dose may be combined with LANT to achieve the same therapeutic efficacy as that obtained with higher doses of cisplatin monotreatment. The combination of LANT and cisplatin suggests that LANT may enhance the therapeutic efficiency of low doses of cisplatin, decrease treatment times and improve patient outcomes. FAU - Lee, Gee Young AU - Lee GY AD - Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA. FAU - Myers, Jonte A AU - Myers JA AD - Department of Learning Sciences, College of Education and Human Development, Georgia State University, Atlanta, GA 30303, USA. FAU - Perez, Sandra M AU - Perez SM AD - Department of Epidemiology and Biostatistics, School of Community and Rural Health, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA. FAU - Singh, Karan P AU - Singh KP AD - Department of Epidemiology and Biostatistics, School of Community and Rural Health, The University of Texas Health Science Center at Tyler, Tyler, TX 75708, USA. FAU - Green, Hadiyah N AU - Green HN AD - Department of Surgery, Morehouse School of Medicine, Atlanta, GA 30310, USA. LA - eng PT - Journal Article DEP - 20200922 PL - Greece TA - Int J Oncol JT - International journal of oncology JID - 9306042 RN - 7440-57-5 (Gold) RN - Q20Q21Q62J (Cisplatin) SB - IM MH - Cell Line, Tumor MH - Cisplatin/*therapeutic use MH - Combined Modality Therapy MH - Gold/*administration & dosage MH - Head and Neck Neoplasms/*therapy MH - Humans MH - *Laser Therapy MH - *Nanotubes MH - Squamous Cell Carcinoma of Head and Neck/*therapy OTO - NOTNLM OT - cisplatin OT - low dose OT - combination therapy OT - gold nanorods OT - lasers OT - nanotherapy OT - adjuvant therapy EDAT- 2021/01/26 06:00 MHDA- 2021/09/14 06:00 CRDT- 2021/01/25 08:43 PHST- 2020/04/06 00:00 [received] PHST- 2020/07/23 00:00 [accepted] PHST- 2021/01/26 06:00 [pubmed] PHST- 2021/09/14 06:00 [medline] PHST- 2021/01/25 08:43 [entrez] AID - 10.3892/ijo.2020.5126 [doi] PST - ppublish SO - Int J Oncol. 2020 Nov;57(5):1169-1178. doi: 10.3892/ijo.2020.5126. Epub 2020 Sep 22.